Edward White

H.C. Wainwright & Co.

Edward P. White is the managing director, senior biotechnology analyst, at H.C. Wainwright & Co., where his research coverage focus is on small to mid-cap life sciences companies. He formerly was a senior biotech equity research analyst at FBR & Co. Prior to FBR, he worked in several healthcare equity research groups, including Deutsche Bank Securities and BMO Capital Markets. He also worked for six years as a Senior Buyside Healthcare Research Analyst at Mitsubishi UFJ Trust.

Recent Articles

Biopharma Gains Another Shot on Goal With IND Approval 01/26/2023

The firm's CD19- and CD3-targeting monoclonal antibody is now cleared for evaluation in a Phase I clinical trial, noted an H.C. Wainwright & Co. report.

Biopharma Creating COVID Drug Gets US$8.2M From the DOD 01/24/2023

This tranche, other cash and cash equivalents, and current cash flow are sufficient to get the developer of immunotherapeutics through 2023, noted an H.C. Wainwright & Co. report.

Biopharma Asks for Emergent Use in US of New COVID Drug 09/29/2022

The requested approval is specifically for critically ill patients, a population for which the U.S. Food and Drug Administration granted the therapeutic fast track status, noted an H.C. Wainwright & Co. report.


Recent Quotes

"RLMD has approximately $15.1M in cash and cash equivalents on its balance sheet, which should fund operations through the end of this calendar year."

— Edward White, FBR & Co. (2/12/16)
more >

"RLMD reaffirmed 2016 timelines and developmental goals for its product pipeline."

— Edward White, FBR & Co. (1/26/16)
more >

"The results from the MAD study confirm the safety and tolerability of RMLD's drug."

— Edward White, FBR & Co. (1/4/16)
more >

"We maintain our Buy rating on CVM, which has more than $14M on its balance sheet."

— Edward White, Laidlaw & Company (11/3/14)
more >

"Photos of RXII's treated patients showed significant improvement."

— Edward White, Laidlaw & Company (10/8/14)
more >

"CVM's Multikine has multiple applications, any of which could lead to significant market opportunities."

— Edward White, Laidlaw & Company (9/24/14)
more >

"RXII's plan to restructure the 1301 study cohorts is a strong positive."

— Edward White, Laidlaw & Company (9/11/14)
more >

"RXII should have preliminary Phase 2a trial data by end of September."

— Edward White, Laidlaw & Company (9/3/14)
more >



Due to permission requirements, not all quotes are shown.